WO2013100870A1 - New antipsychotic compositions - Google Patents

New antipsychotic compositions Download PDF

Info

Publication number
WO2013100870A1
WO2013100870A1 PCT/TR2012/000205 TR2012000205W WO2013100870A1 WO 2013100870 A1 WO2013100870 A1 WO 2013100870A1 TR 2012000205 W TR2012000205 W TR 2012000205W WO 2013100870 A1 WO2013100870 A1 WO 2013100870A1
Authority
WO
WIPO (PCT)
Prior art keywords
particle size
pharmaceutical composition
less
agents
composition according
Prior art date
Application number
PCT/TR2012/000205
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013100870A1 publication Critical patent/WO2013100870A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Definitions

  • the present invention relates to pharmaceutical compositions comprising escitalopram and fields of use thereof.
  • Citalopram which was first disclosed in the patent numbered DE2657 013 is a selective serotonin reuptake inhibitor.
  • the average daily dose of citalopram is 20 mg, and it is marketed in citalopram hydrobromide and citalopram hydrochloride salt forms.
  • the active agent is sold in 10 and 20 mg film coated tablet and oral solution dosage forms on the market. Said drug is used in the treatment of acute and major depressive diseases in adults and adolescents aged between 12 and 17.
  • escitalopram is a very low-soluble active agent and this low solubility of the active agent reduces the therapeutically effective dose taken by the patient.
  • the patients increase the dose of the drug in order to obtain therapeutic effect that they need.
  • increased drug dose increase the possibility of side effects and therefore it is not generally preferred.
  • the pharmaceutical compositions comprising escitalopram are not applicable to all types of dosage forms due to low solubility of the active agent. For instance, when water soluble dosage forms are developed, it is quite difficult to obtain the required solubility characteristics.
  • solubility characteristics can be improved in the pharmaceutical compositions prepared by using an active agent having an average particle size (d 5 o) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1.
  • average particle size used herein refers to average particle size by volume and it is also shown with d 50 in short. In this sense, the term d 50 signifies that half of the said substance by volume has a particle size over the value stated with d 50 and the other half of the substance by volume has a particle size below the value stated with d 50.
  • d 95 signifies that 95% of the said substance by volume has a particle size below the stated value and 5% of the said substance by volume has a particle size over the stated value.
  • D 5 o and d 95 particle sizes of the active agent comprised in the pharmaceutical compositions according to the present invention can be measured with one of the known measuring devices, for instance with a device which measures particle distribution by laser diffraction (for instance, Malvern Mastersizer etc.).
  • compositions according to the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be prepared in any dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged release tablet, modified release tablet, delayed release tablet.
  • the obtained tablets can optionally be presented in film coated tablet form.
  • the film coating solution that can be used for film coating of the formulations according to the present invention comprises at least one excipient that can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; and synthetic polymers such as polyvinyl acetal diethyl amino acetate, amino alkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan or combinations thereof.
  • compositions of the present invention can be prepared optionally in water soluble dosage forms such as effervescent tablet.
  • Said water soluble dosage forms can be effervescent or non-effervescent.
  • escitalopram used throughout the text refers to said active agent's pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms or combinations thereof.
  • the active agent used in the compositions of the present invention is preferably escitalopram oxalate salt.
  • a characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 0 ) less than 20 ⁇ and a (d 50 ) / (d 5 ) particle size ratio less than 1 is that said pharmaceutical compositions comprise at least one pharmaceutically acceptable excipient in addition to the active agent.
  • excipients that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 5 o) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising binders, disintegrants, viscosity enhancing agents, filling agents, drying agents, surfactants, stabilizing agents, oiling agents, lubricants, diluents, glidants, wetting agents, coating agents designed in order to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulgators, anti-foaming substances, protective agents, solvent or solvent mixtures, colouring agents and complexing agents or combinations thereof.
  • the disintegrants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate or combinations thereof.
  • the diluents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch and starch derivatives (for instance corn starch), sodium chloride, sucrose, talc, xylitol or the combinations thereof.
  • the lubricants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
  • the oiling agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc or combinations thereof.
  • binders that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 9 ) particle size ratio less than 1 can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, starch or combinations thereof.
  • the effervescent acids that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 5 o) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid, maleic acid or hydrates, anhydrates or combinations thereof.
  • the effervescent bases that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d9 5 ) particle size ratio less than 1 can be selected from a group comprising sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate or combinations thereof.
  • the pH regulating agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 5 o) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising citrate, phosphate, carbonate, tartrate, fumarate, acetate, maleate and amino acid salts or combinations thereof.
  • the surfactants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 9 ) particle size ratio less than 1 can be selected from a group comprising sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol or combinations thereof.
  • the stabilizing agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising tocopherol, tetrasoidum edetate, nicotinamide, cyclodextrin or combinations thereof.
  • sweetener and/or taste regulating agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 5 o) less than 20 ⁇ and a (d 50 ) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride or combinations thereof.
  • flavouring agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 50 ) less than 20 ⁇ and a (d 5 o) / (d 95 ) particle size ratio less than 1 can be selected from a group comprising menthol, lemon, orange, vanilla, strawberry, raspberry, caramel or combinations thereof.
  • a characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that particle size (d 5 o) of the active agent is less than 15 ⁇ and the ratio of (d 50 ) / (d 95 ) particle sizes of the active agent is less than 0.75.
  • Another characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that particle size (d 50 ) of the active agent is less than 13 ⁇ and the ratio of (d 50 ) / (d 95 ) particle sizes of the active agent is less than 0.75.
  • compositions of the present invention comprising escitalopram as the active agent is that particle size (d 50 ) of the active agent is in the range of 1 ⁇ to 13 ⁇ and the ratio of (d 50 ) / (d 95 ) particle sizes of the active agent is less than 0.50.
  • a characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that said pharmaceutical compositions comprise the active agent in the range of 0.1 to 10% by weight, preferably in the range of 0.1 to 5% by weight.
  • compositions of the present invention can be produced by one of the methods in the prior art. Wet granulation, dry granulation, dry blending, direct compression methods can be listed among these production methods. One or more of these methods can be used together for production of the compositions.
  • compositions of the present invention can be used in the treatment and/or prevention of depression (major depressive disorder), geriatrics, obesity, alcoholism, neurotic disorders, anxiety disorder [Agoraphobia (aeroacrophobia) or non-agoraphobia panic disorder, social anxiety disorder, generalized anxiety disorder and obsessive compulsive disorder], post-traumatic stress disorder, panic attack.
  • depression major depressive disorder
  • geriatrics obesity
  • alcoholism neurotic disorders
  • anxiety disorder [Agoraphobia (aeroacrophobia) or non-agoraphobia panic disorder
  • social anxiety disorder generalized anxiety disorder and obsessive compulsive disorder
  • post-traumatic stress disorder panic attack.
  • Escitalopram, disintegrant and diluent are mixed for production of the formulation given.
  • the sweetener is added into the mixture and then the mixture is treated with the lubricant.
  • the final mixture obtained is compressed into tablets.
  • the tablets obtained can optionally be film- coated with film coated agent
  • escitalopram and effervescent couple are wet-granulated with the granulation solution comprising the filling agent and the binder.
  • the obtained granules are dried and the sweetener, flavouring agent and then lubricant are added into the granules.
  • the granules can optionally be compressed in tablet form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising escitalopram and fields of use thereof.

Description

NEW ANTIPSYCHOTIC COMPOSITIONS
The present invention relates to pharmaceutical compositions comprising escitalopram and fields of use thereof.
Citalopram which was first disclosed in the patent numbered DE2657 013 is a selective serotonin reuptake inhibitor. The average daily dose of citalopram is 20 mg, and it is marketed in citalopram hydrobromide and citalopram hydrochloride salt forms.
Pharmaceutically more effective (S)-enantiomer of citalopram is escitalopram with the molecule formula (S)-l -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)- l,3-dihydroisobenzofuran-5-carbonitrile which was first disclosed in the patent numbered US 4 943 590.
Figure imgf000002_0001
Formula (I)
The active agent is sold in 10 and 20 mg film coated tablet and oral solution dosage forms on the market. Said drug is used in the treatment of acute and major depressive diseases in adults and adolescents aged between 12 and 17.
However, escitalopram is a very low-soluble active agent and this low solubility of the active agent reduces the therapeutically effective dose taken by the patient.
In this case, the patients increase the dose of the drug in order to obtain therapeutic effect that they need. However, increased drug dose increase the possibility of side effects and therefore it is not generally preferred.
In other aspect, the pharmaceutical compositions comprising escitalopram are not applicable to all types of dosage forms due to low solubility of the active agent. For instance, when water soluble dosage forms are developed, it is quite difficult to obtain the required solubility characteristics.
As a result of the studies they conducted in order to improve solubility characteristics of the active agent, the inventors have found that solubility characteristics can be improved in the pharmaceutical compositions prepared by using an active agent having an average particle size (d5o) less than 20 μηι and a (d50) / (d95) particle size ratio less than 1. The term "average particle size" used herein refers to average particle size by volume and it is also shown with d50 in short. In this sense, the term d50 signifies that half of the said substance by volume has a particle size over the value stated with d50 and the other half of the substance by volume has a particle size below the value stated with d50.
The term d95 signifies that 95% of the said substance by volume has a particle size below the stated value and 5% of the said substance by volume has a particle size over the stated value. D5o and d95 particle sizes of the active agent comprised in the pharmaceutical compositions according to the present invention can be measured with one of the known measuring devices, for instance with a device which measures particle distribution by laser diffraction (for instance, Malvern Mastersizer etc.).
The pharmaceutical compositions according to the present invention comprising escitalopram having a particle size (d50) less than 20 μιη and a (d50) / (d95) particle size ratio less than 1 can be prepared in any dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged release tablet, modified release tablet, delayed release tablet.
In the case that the pharmaceutical compositions according to the present invention are in tablet dosage form, the obtained tablets can optionally be presented in film coated tablet form. The film coating solution that can be used for film coating of the formulations according to the present invention comprises at least one excipient that can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; and synthetic polymers such as polyvinyl acetal diethyl amino acetate, amino alkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan or combinations thereof.
An advantage of the pharmaceutical compositions of the present invention is that the formulations can be prepared optionally in water soluble dosage forms such as effervescent tablet. Said water soluble dosage forms can be effervescent or non-effervescent.
The term "escitalopram" used throughout the text refers to said active agent's pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms or combinations thereof. Though, the active agent used in the compositions of the present invention is preferably escitalopram oxalate salt.
A characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d 0) less than 20 μηι and a (d50) / (d 5) particle size ratio less than 1 is that said pharmaceutical compositions comprise at least one pharmaceutically acceptable excipient in addition to the active agent.
The excipients that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d5o) less than 20 μπι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising binders, disintegrants, viscosity enhancing agents, filling agents, drying agents, surfactants, stabilizing agents, oiling agents, lubricants, diluents, glidants, wetting agents, coating agents designed in order to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulgators, anti-foaming substances, protective agents, solvent or solvent mixtures, colouring agents and complexing agents or combinations thereof.
The disintegrants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μπι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate or combinations thereof.
The diluents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μιη and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch and starch derivatives (for instance corn starch), sodium chloride, sucrose, talc, xylitol or the combinations thereof.
The lubricants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μιη and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
The oiling agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μηι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc or combinations thereof. The binders that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μπι and a (d50) / (d9 ) particle size ratio less than 1 can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, starch or combinations thereof.
The effervescent acids that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μιη and a (d5o) / (d95) particle size ratio less than 1 can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid, maleic acid or hydrates, anhydrates or combinations thereof.
The effervescent bases that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μηι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate or combinations thereof.
The pH regulating agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d5o) less than 20 μηι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising citrate, phosphate, carbonate, tartrate, fumarate, acetate, maleate and amino acid salts or combinations thereof. The surfactants that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μπι and a (d50) / (d9 ) particle size ratio less than 1 can be selected from a group comprising sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol or combinations thereof.
The stabilizing agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μηι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising tocopherol, tetrasoidum edetate, nicotinamide, cyclodextrin or combinations thereof.
The sweetener and/or taste regulating agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d5o) less than 20 μπι and a (d50) / (d95) particle size ratio less than 1 can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride or combinations thereof. The flavouring agents that can be used in the pharmaceutical compositions of the present invention comprising escitalopram having a particle size (d50) less than 20 μπι and a (d5o) / (d95) particle size ratio less than 1 can be selected from a group comprising menthol, lemon, orange, vanilla, strawberry, raspberry, caramel or combinations thereof.
A characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that particle size (d5o) of the active agent is less than 15 μιη and the ratio of (d50) / (d95) particle sizes of the active agent is less than 0.75. Another characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that particle size (d50) of the active agent is less than 13 μηι and the ratio of (d50) / (d95) particle sizes of the active agent is less than 0.75.
Another characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that particle size (d50) of the active agent is in the range of 1 μηι to 13 μπι and the ratio of (d50) / (d95) particle sizes of the active agent is less than 0.50.
A characteristic feature of the pharmaceutical compositions of the present invention comprising escitalopram as the active agent is that said pharmaceutical compositions comprise the active agent in the range of 0.1 to 10% by weight, preferably in the range of 0.1 to 5% by weight.
The pharmaceutical compositions of the present invention can be produced by one of the methods in the prior art. Wet granulation, dry granulation, dry blending, direct compression methods can be listed among these production methods. One or more of these methods can be used together for production of the compositions.
The pharmaceutical compositions of the present invention can be used in the treatment and/or prevention of depression (major depressive disorder), geriatrics, obesity, alcoholism, neurotic disorders, anxiety disorder [Agoraphobia (aeroacrophobia) or non-agoraphobia panic disorder, social anxiety disorder, generalized anxiety disorder and obsessive compulsive disorder], post-traumatic stress disorder, panic attack.
The examples below are given in order to explain the pharmaceutical compositions of the present invention; yet, the pharmaceutical compositions of the present invention are not limited to these examples. EXAMPLES
1. Tablet
Figure imgf000007_0001
Escitalopram, disintegrant and diluent are mixed for production of the formulation given. The sweetener is added into the mixture and then the mixture is treated with the lubricant. The final mixture obtained is compressed into tablets. The tablets obtained can optionally be film- coated with film coated agent
2. Effervescent Granule
Figure imgf000008_0001
In order to obtain the effervescent granule composition given, escitalopram and effervescent couple are wet-granulated with the granulation solution comprising the filling agent and the binder. The obtained granules are dried and the sweetener, flavouring agent and then lubricant are added into the granules.
The granules can optionally be compressed in tablet form.

Claims

1) A pharmaceutical composition comprising escitalopram, characterized in that the active agent has a d50 particle size less than 20 μπι and a (ds0) / (d95) particle size ratio less than 1.
2) The pharmaceutical composition according to claim 1, characterized in that d50 particle size of the active agent is less than 15 μιη and (d50) / (d95) particle size ratio of the active agent is less than 0.75.
3) The pharmaceutical composition according to claim 2, characterized in that d50 particle size of the active agent is less than 13 μηι and (d5o) / (d95) particle size ratio of the active agent is less than 0.75.
4) The pharmaceutical composition according to claim 2 or 3, characterized in that d50 particle size of the active agent is in the range of 1 μπι to 13 μηι and (d50) / (d95) particle size ratio of the active agent is less than 0.50.
5) The pharmaceutical composition according to any preceding claims, characterized in that escitalopram used in the compositions is in the form of its pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms or combinations thereof.
6) The pharmaceutical composition according to claim 5, characterized in that escitalopram is in its oxalate salt form.
7) The pharmaceutical composition according to any preceding claims, characterized in that said composition is in any dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged release tablet, modified release tablet, delayed release tablet.
8) A dosage form according to claim 7, characterized in that in the case that said dosage form is in tablet form, the tablets can optionally be film coated.
9) A dosage form according to claim 7, characterized in that, said dosage form is optionally in the form of effervescent.
10) The pharmaceutical composition according to any preceding claims, characterized in that said composition comprises at least one pharmaceutically acceptable excipient in addition to the active agent.
1 1) The pharmaceutical composition according to claim 8, characterized in that said composition comprises at least one pharmaceutically acceptable excipient selected from a group comprising disintegrants, viscosity enhancing agents, filling agents, drying agents, surfactants, stabilizing agents, oiling agent, lubricants, diluents, glidants, wetting agents, coating agents designed in order to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulgators, anti-foaming agents, protective agents, solvent or solvent mixtures, colouring agents and complexing agents or combinations thereof.
12) The pharmaceutical composition according to claim 11, characterized in that the effervescent acid used in said compositions is selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid, maleic acid; hydrates, anhydrates or combinations thereof.
13) The pharmaceutical composition according to claim 11, characterized in that the effervescent base used in said compositions is selected from a group comprising sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate or combinations thereof
14) The pharmaceutical composition according to any preceding claims characterized in that said composition comprises escitalopram in the range of 0.1 to 10% by weight, which has a d50 particle size less than 20 μπι and a (d50) / (d95) particle size ratio less than 1.
15) The pharmaceutical composition according to claim 14, characterized in that said composition comprises escitalopram in the range of 0.1 to 5% by weight, which has a d50 particle size less than 20 μηι and a (d50) / (d95) particle size ratio less than 1.
16) The pharmaceutical composition according to any preceding claims, characterized in that said composition is used in the treatment and/or prevention of depression (major depressive disorder), geriatrics, obesity, alcoholism, neurotic disorders, anxiety disorder [Agoraphobia (aeroacrophobia) or non-agoraphobia panic disorder, social anxiety disorder, generalized anxiety disorder and obsessive compulsive disorder], post-traumatic stress disorder, panic attack.
PCT/TR2012/000205 2011-12-02 2012-12-03 New antipsychotic compositions WO2013100870A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201111953 2011-12-02
TR2011/11953 2011-12-02

Publications (1)

Publication Number Publication Date
WO2013100870A1 true WO2013100870A1 (en) 2013-07-04

Family

ID=47997759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000205 WO2013100870A1 (en) 2011-12-02 2012-12-03 New antipsychotic compositions

Country Status (1)

Country Link
WO (1) WO2013100870A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105343026A (en) * 2015-10-30 2016-02-24 山东京卫制药有限公司 Formula and preparation process of escitalopram oxalate effervescent tablet
CN111514110A (en) * 2020-05-07 2020-08-11 福建海西新药创制有限公司 Pharmaceutical composition containing escitalopram oxalate and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2657013A1 (en) 1976-01-14 1977-07-28 Kefalas As PHTHALANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE
US4943590A (en) 1988-06-14 1990-07-24 H. Lundbeck A/S Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof
WO2007050697A2 (en) * 2005-10-26 2007-05-03 Azur Pharma Iii Limited Compositions and methods for the administration psychotropic drugs which modulate body weight
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2657013A1 (en) 1976-01-14 1977-07-28 Kefalas As PHTHALANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE
US4943590A (en) 1988-06-14 1990-07-24 H. Lundbeck A/S Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof
WO2007050697A2 (en) * 2005-10-26 2007-05-03 Azur Pharma Iii Limited Compositions and methods for the administration psychotropic drugs which modulate body weight
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105343026A (en) * 2015-10-30 2016-02-24 山东京卫制药有限公司 Formula and preparation process of escitalopram oxalate effervescent tablet
CN111514110A (en) * 2020-05-07 2020-08-11 福建海西新药创制有限公司 Pharmaceutical composition containing escitalopram oxalate and preparation method thereof

Similar Documents

Publication Publication Date Title
EP2760821B1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
ES2727861T3 (en) Capsule formulation comprising Montelukast and Levocetirizine
JP4707073B2 (en) Particulate pharmaceutical composition for oral administration of atorvastatin
ES2673182T3 (en) Pharmaceutical composition containing a diamine derivative
RU2671491C2 (en) Complex granulated composition with improved stability, including levocetrizine and monteleukast
WO2007108010B1 (en) Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
WO2013081565A1 (en) Pharmaceutical compositions comprising roflumilast and terbutaline
EP2540318B1 (en) Sustained-release solid preparation for oral use
JP2020518611A (en) Compositions with improved water solubility and bioavailability
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
WO2013100870A1 (en) New antipsychotic compositions
WO2013109225A1 (en) Pharmaceutical tablet formulations comprising ceftibuten
WO2011093828A2 (en) Solid dosage forms comprising cefprozil
WO2014104989A1 (en) Pharmaceutical compositions comprising aripiprazole
WO2014007775A1 (en) A novel formulation having fast dissolution
KR20210152280A (en) Single chewable tablet comprising montelukast and levocetirizine with improved stability and a process for the preparation thereof
EP2959889A1 (en) Orally disintegrating formulations of loxoprofen
JP2006510665A (en) New oral immediate release dosage form
WO2013081567A1 (en) Effervescent antipsychotic formulations
WO2013109230A1 (en) Pharmaceutical compositions comprising tadalafil
WO2019025934A1 (en) A stable oral pharmaceutical composition of pimavanserin
WO2013095315A1 (en) Formulations comprising dexketoprofen (particle size 300-2500 micrometer)
WO2013100873A1 (en) Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
WO2013100879A1 (en) Pharmaceutical compositions comprising quetiapine
WO2013077830A1 (en) Synergistilly active combinations of roflumilast and carmoterol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12834598

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12834598

Country of ref document: EP

Kind code of ref document: A1